ALS (amyotrophic lateral sclerosis), a fatal motoneuron (motor neuron) disease, occurs in clinically indistinguishable sporadic (sALS) or familial (fALS) forms. Most fALS-related mutant proteins identified so far are prone to misfolding, and must be degraded in order to protect motoneurons from their toxicity. This process, mediated by molecular chaperones, requires proteasome or autophagic systems. Motoneurons are particularly sensitive to misfolded protein toxicity, but other cell types such as the muscle cells could also be affected. Muscle-restricted expression of the fALS protein mutSOD1 (mutant superoxide dismutase 1) induces muscle atrophy and motoneuron death. We found that several genes have an altered expression in muscles of transgenic ALS mice at different stages of disease. MyoD, myogenin, atrogin-1, TGFβ1 (transforming growth factor β1) and components of the cell response to proteotoxicity [HSPB8 (heat shock 22 kDa protein 8), Bag3 (Bcl-2-associated athanogene 3) and p62] are all up-regulated by mutSOD1 in skeletal muscle. When we compared the potential mutSOD1 toxicity in motoneuron (NSC34) and muscle (C2C12) cells, we found that muscle ALS models possess much higher chymotryptic proteasome activity and autophagy power than motoneuron ALS models. As a result, mutSOD1 molecular behaviour was found to be very different. MutSOD1 clearance was found to be much higher in muscle than in motoneurons. MutSOD1 aggregated and impaired proteasomes only in motoneurons, which were particularly sensitive to superoxide-induced oxidative stress. Moreover, in muscle cells, mutSOD1 was found to be soluble even after proteasome inhibition. This effect could be associated with a higher mutSOD1 autophagic clearance. Therefore muscle cells seem to manage misfolded mutSOD1 more efficiently than motoneurons, thus mutSOD1 toxicity in muscle may not directly depend on aggregation.
Introduction
ALS (amyotrophic lateral sclerosis) is a fatal adult-onset motoneuron (motor neuron) disease, in which progressive motoneuron death occurs in different areas of the central nervous system. Motoneurons located in the cerebral cortex, in the brain stem and in the anterior horns of the spinal cord are those mainly involved, but their selective loss may vary considerably between affected individuals [1] . Most ALS cases occur as sporadic forms. Approximately 10-15 % of ALS cases are fALS (familial ALS), but these are clinically indistinguishable from sALS (sporadic ALS). Several genes have been linked to fALS. The first mutations identified in fALS are those occurring in the gene coding for the SOD1 (superoxide dismutase 1), a free radical scavenger enzyme present in almost all cells. Other mutant genes identified more recently are those coding for TDP-43 (43 kDa transactive response DNA-binding protein), FUS/TLS (fused in sarcoma/translocated in liposarcoma), optineurin, etc. (for a review see [2] ). Most, but not all, of these are point mutations, which are thought to destabilize protein conformation lead to misfolding [3] . The misfolded proteins may then result in protein accumulation or may affect several cellular functions, e.g. inducing axonal transport alterations, mitochondrial and/or proteasome dysfunctions [1, 3, 4] . Even the recently identified ALS-associated gene C9ORF72 [5] [6] [7] may activate similar pathways. Its mutated form carries a hexanucleotide (GGGGCC) repeat expansion in the 5 -untranslated region, suggesting an alteration of RNA metabolism that could lead to RNA toxicity [5, 6] . Nevertheless, it has been found recently that this abnormal hexanucleotide repeat expansion is able to generate highly hydrophobic dipeptides by RAN (repeat-associated non-ATG) translation [8] [9] [10] . This mutant gene is not only associated with ALS, but also, like mutations of TDP-43 or FUS/TLS, associated with FTD (frontotemporal dementia), or cases with a mixed contribution of ALS and FTD [5, 6, 10, 11] . Misfolded proteins and hydrophobic dipeptides may directly perturb several intracellular mechanisms and trigger neurotoxicity, but they are also capable of aggregating in neurons, and particularly in affected motoneurons [8, [12] [13] [14] . In fact, proteins that aggregate intracellularly generate insoluble inclusions that are a key neuropathological hallmark of ALS and other neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and Huntington's diseases).
Alteration of misfolded protein clearance in motoneurons
By analysing immortalized motoneurons, the molecular and biochemical behaviours of mutSOD1 (mutant SOD1) or of a disease-associated truncated TDP-43 form [CTF (C-terminal fragment)-TDP-43], potential mechanisms of neurotoxicity of misfolded proteins may become evident [15] [16] [17] [18] [19] . For example, the formation of HMW (high-molecular-mass) species of mutSOD1 or TDP-43 fragment is related to intracellular aggregate formation, which is correlated with a marked impairment or overwhelming of proteasome activity. The same proteins also showed an altered intracellular distribution [15, 16] . Indeed, in the case of mutSOD1, its nuclear bioavailability is reduced and this might result in a decreased nuclear protection from free radical species [15] . In support of this hypothesis, we found an increase in hydrogen-peroxide-induced DNA damage in cells expressing mutSOD1 when compared with wtSOD1 (wild-type SOD1). Also, different mitochondrial alterations have been reported to specifically occur in motoneuronal cells, and proposed to be relevant for the pathogenic mechanisms of ALS. Moreover, mutSOD1-induced alterations in free radical response have also been observed at the mitochondrial level [1, [20] [21] [22] [23] . By evaluating mitochondrial superoxide-induced oxidation using MitoSOX, a mitochondrion-specific fluorogenic dye oxidized by superoxide, in NSC34 models of ALS, we found that motoneurons expressing mutSOD1 are more sensitive to superoxide-induced oxidative stress than cells expressing wtSOD1 [18] . This suggests that mutSOD1, owing to a decreased intracellular bioavailability as a result of sequestration into aggregates, might be less efficient against free radical species damage [15] .
Alteration of the normal protein localization could also be responsible for TDP-43 cytotoxicity, which, once excluded from the nucleus, may lose its normal activity in RNA metabolism [24] [25] [26] [27] .
The misfolded mutSOD1 and TDP-43 proteins not only aggregate and/or impair/overwhelm the proteasome capacity, but also can alter another degradative pathway: the autophagy process. In fact, both mutSOD1 and TDP-43 are capable of blocking the autophagic flux when expressed in motoneurons [12, 28] . This could be a mechanism responsible for the accumulation of mutSOD1 and TDP-43 in affected cells [16] . Interestingly, several proteins involved in these degradative pathways have been found sequestered in the inclusions observed in ALS patients [7] . Thus the fact that misfolded proteins perturb the degradative pathways and sequestered proteins accumulate as a result gives rise to a vicious cycle that leads to a further accumulation of insoluble proteins and inclusions formation [17] . Among these sequestered proteins are several molecular chaperones, such as HSP70 (heat-shock protein 70) and HSP40, supporting the idea that the aggregation process occurs before alterations of the degradative pathways. Aggregation may occur already when misfolded proteins are recognized by the chaperones, and/or when they are actively transported to the degradative systems (cargo delivery to the proteasome or to the autophagosomes). In the case of autophagy, the cargo must be delivered by dynein at the MTOC (microtubule-organizing centre), which is also the site of formation of the aggresomes [19, [29] [30] [31] . Interestingly, dynein, but not the other motor protein kinesin, can be sequestered by aggregates [30, 32, 33] . Despite all of the evidence, the roles of aggresomes, aggregates and/or inclusions and their cytotoxicity are still largely debated. In any case, they represent a powerful marker of protein misfolding to follow a correlation with the neurodegenerative processes [34] . In fact, it is expected that increased misfolded ALS protein clearance should prevent its accumulation and aggregation, possibly blocking the downstream cascades of events, which might lead to motoneuron death in ALS. Following this idea, we used a small HSP, known as HSPB8 (heat shock 22 kDa protein 8), to test the hypothesis that, by assisting protein folding, we might reduce protein aggregation and fully restore functional proteasome activity and/or a normal autophagic flux. All of the data obtained demonstrated that HSPB8 almost completely abolished aggregation of both mutSOD1 and TDP-43 by increasing their autophagic clearance. Interestingly, HSPB8 has no effect on wtSOD1 or wild-type TDP-43 turnover [16] . Notably, the effect of HSPB8 does not require proteasome activity, since its pro-degradative action is present even when the proteasome is blocked with specific inhibitors [16] . In addition, the proteasome is not overwhelmed by prevention of mutSOD1 aggregation, indicating that soluble mutSOD1 is not directed to this pathway for its degradation [16] . On the other hand, HSPB8 pro-degradative activity is prevented by autophagy inhibition. This resulted in a dramatic increase in mutSOD1 aggregates present in our ALS motoneuronal models [16] . However, HSPB8 expression does not directly activate autophagy, but seems to facilitate (or restore) the already activated (but partially blocked) autophagic flux. The pro-autophagic role of HSPB8 involves the recruitment of the co-chaperone Bag3 (Bcl-2-associated athanogene 3; possibly after the recognition of misfolded protein species), the chaperone Hsc70 (heat-shock cognate 70 stress protein) and the ubiquitinating enzyme CHIP (C-terminus of the Hsc70-interacting protein). This generates a multiheteromeric complex, which is known to selectively increase autophagic removal of misfolded proteins [12, 16, 28, [35] [36] [37] . In fact, once the complex is formed, CHIP ubiquitinates the target misfolded protein, which is then Several mutant ALS proteins tend to misfold. The protein quality control system, consisting of a combination of molecular chaperones and the degradative pathways, are the first line of defence against the production and accumulation of these misfolded proteins. On the basis of our studies, muscle cells more efficiently remove misfolded proteins than motoneuronal cells and therefore are less sensitive to their toxicity. In fact, in motoneuronal cells, misfolded ALS proteins accumulate inside the cells and generate protein aggregates and inclusions. These species can induce alteration at a nuclear level, causing DNA damage (1), or affect the mitochondria, causing mitochondrial swelling (2) . The misfolded species may accumulate because their production overwhelms the proteasome capabilities (3) to remove aberrant proteins, as well as lead to a blockage of the autophagic flux (4) . The accumulation of proteins into aggregates may also induce alteration of the fast axonal transport processes (5) . In muscle cells, the presence of mutant misfolded ALS proteins also results in the perturbation of several cellular processes (i.e. alteration of gene transcription to respond to protein toxicity), but in muscle cells apparently these aberrant activities are not linked to protein accumulation (misfolded ALS proteins remain soluble). In muscle cells, the proteasome seems to possess a normal activity (6), the autophagic flux seems to proceed to completion (7) and mitochondria appear to be normal (8) .
recognized by the protein p62 for its delivery to the forming autophagosome [37] .
Interestingly, autophagy activation has been reported in lumbar spinal cord of tg (transgenic) G93A-SOD1 mice, since several autophagolysosomal structures were present in affected surviving motoneurons [16, 38] . We also found that in the same mice at the end-stage of disease, most of the surviving motoneurons contain mutSOD1 and also express very high levels of HSPB8. This strongly suggests that HSPB8 might exert a protective function on these motoneuronal cells.
Since studies of HSPB8 physiological tissue distribution have demonstrated that this chaperone is highly expressed in muscle [12, 28] , we analysed whether its expression can be further increased by mutSOD1 in this tissue. Our preliminary data obtained in ALS mice models clearly indicate that there is a progressive and dramatic increase in HSPB8 (and also in Bag3) expression in muscle of tg G93A-SOD1 mice, compared with age-matched non-tg mice and mice expressing wtSOD1 (V. Crippa, A. Boncoraglio, R. Galbiati, T. Aggarwal, P. Rusmini, E. Giorgetti, R. Cristofani, S. Carra, M. Pennuto and A. Poletti, unpublished work).
Other cellular targets of misfolded protein toxicity
In our view, these data are particularly relevant to clarify some of the aspects related to potential toxicity of ALS proteins. In fact, evidence suggests that motoneuron death in ALS is non-cell-autonomous [39] . In addition to motoneurons, other non-neuronal cells might contribute to either disease onset or progression (or both). This non-neuronal toxicity to motoneurons might arise from surrounding astrocytes or Schwann cells from chemotactically attracted microglial cells or from target muscle cells. Several studies have thus been carried out to understand whether mutSOD1 toxicity is confined to motoneurons, or whether the other cell types are also directly affected, thus playing a direct role in the disease. Although several lines of evidence have helped us to unravel the involvement of glial and microglial cells that reside in the central nervous system [40, 41] , less data are available on the role of muscle cells and its contribution to ALS is still unclear. Interestingly, dysfunction of skeletal muscles and degeneration of neuromuscular junctions precede disease onset and motoneuron loss in tg ALS mice [42, 43] . Notably, although the reduction in mutSOD1 expression in skeletal muscle of tg ALS mice has no effect on disease progression [44] , the selective expression of mutSOD1 in skeletal muscle induces muscle atrophy and mitochondrial abnormalities, which are typical mutSOD1-induced alterations. Interestingly, mutSOD1-induced muscle damage leads to loss of mutSOD1-negative motoneurons in the anterior horn of the spinal cord [45] [46] [47] . The data suggest that mutSOD1 neurotoxicity can be exerted at different levels and its restricted expression in muscle can be sufficient to induce an ALS-like disease in mice. It is of interest that factors arising from the muscle, i.e. IGF-1 (insulin-like growth factor-1), can increase survival of tg ALS mice [45, [48] [49] [50] acting as trophic factors capable of enhancing survival of spinal cord motoneurons [51, 52] .
Misfolded protein clearance in muscle cells
It is still unclear whether mutSOD1 toxicity directly occurs in muscle cells, and whether this is activated by molecular toxic mechanisms similar to those active in motoneurons. Our data strongly suggest that muscle cells are able to better manage misfolded mutSOD1 species, even if misfolding is an intrinsic property of mutSOD1, and does not depend on the cell environment [53] .
It must be noted that mutSOD1 largely accumulates in the spinal cord, but not in muscle of tg ALS mice. In fact, we observed no difference in the levels and solubility of mutSOD1 in the gastrocnemius muscles of male tg mutSOD1 mice at pre-symptomatic and symptomatic stages compared with both age-matched tg wtSOD1 mice and non-tg mice [54] . Instead, at end-stage mutSOD1 levels in tg ALS mice, the muscle increased 2-fold compared with muscles from age-matched wtSOD1 mice, but no insoluble HMW SOD1 species (oligomers or aggregates) were present [54] . Thus mutSOD1 biochemical behaviour might differ in motoneurons and muscle cells.
Using two specific motoneuronal (NSC34 cell-based) and muscle (C2C12 cell-based) ALS models, we compared the biochemical behaviour and degradative process of wtSOD1 and mutSOD1 proteins in these different cell types. In general, all data demonstrated that misfolded mutSOD1 is cleared at a higher rate in muscle cells than in motoneuronal cells. Apparently the higher degradative power of the muscle cells compared with motoneuronal cells prevented intracellular accumulation of insoluble mutSOD1 species. Interestingly, in both motoneurons and muscle cells, monomeric mutSOD1 levels were lower than wtSOD1 levels [18] . Using fluorescence microscopy analysis, we found that wtSOD1 was diffusely distributed in both motoneurons and muscle cells (either considered under undifferentiated or proliferating/differentiating conditions). In contrast, in motoneuronal cells, mutSOD1 was excluded from nuclei, and accumulated into aggregates, whereas in muscle, mutSOD1 distribution was almost identical with that found for wtSOD1. This suggests that these alterations of intracellular distribution of mutSOD1 occurring in motoneurons, and are possibly responsible for the higher nuclear sensitivity to free radical species with increasing DNA damage (see above and [15] ), do not seem to occur in muscle cells. In addition, in muscle cells, no alteration of MitoSOX oxidation were detectable in the presence of mutSOD1 or wtSOD1, suggesting that these cells are not unprotected against superoxide-induced oxidative stress in mitochondria, as it occurs in motoneuronal cells (see above and [18] ).
All data thus confirmed that no aggregates (or nonaggregated insoluble HMW species) are formed under basal conditions in wtSOD1-or mutSOD1-expressing muscle cells. In addition, mutSOD1 clearance in muscle involves both the proteasome and autophagy, since insoluble mutSOD1 species were detectable when both systems are blocked. Thus the activity of these pathways could be higher in muscle cells than in motoneuronal cells, helping to quickly remove the misfolded mutSOD1 (Figure 1) . Indeed, by measuring the basal functions of the three different proteasome activities (chymotryptic, post-acidic and tryptic activities), we found that only the chymotryptic activity was significantly higher in muscle than motoneuronal cells. Notably, muscle cell differentiation (under low-serum conditions) resulted in a further increase in the chymotryptic proteasome activity [18] . By testing the autophagic power, using LC3 (light chain 3) and p62 markers, we found that motoneuronal cells possess lower activities of proteasome and basal autophagy, but a much higher autophagic potential in response to mutSOD1 than muscle C2C12 cells [18] . However, our data also clearly established that autophagic flux blockage seems to occur mainly in mutSOD1 motoneuronal cells, and not in muscle cells [18] . Similar data have been obtained with a FL (full-length) TDP-43 or a C TDP-43 (disease-associated fragment of TDP-43). In fact, in motoneuronal cells only C TDP-43 aggregated, but proteasome or autophagy inhibition cause aggregation of both FL and C TDP-43. However, we observed that autophagy seems more involved in these proteins clearance, particularly for the C TDP- 43 (Figure 1 ).
Misfolded protein-induced alteration in muscle cells
Since, if present, toxicity of mutSOD1 (but perhaps also of TDP-43) in muscle may not be linked to its aggregation, we tested whether a potential direct alteration induced by mutSOD1 in muscle cells can be observed at the level of expression of typical genes controlling muscle pathways activated by nerve injury or muscular atrophy. In our C2C12-based ALS model, we evaluated gene expression modifications of mRNAs coding for the proteins MyoD and myogenin (two myogenic regulatory factors) as well as for atrogin-1, calpain-1 and TGFβ1, which are markers of muscle fibre damage or atrophy. The results have shown that in muscle cells, mutSOD1 induced a significant increase in MyoD, myogenin and TGFβ1 mRNAs, whereas no variations were seen with wtSOD1. Calpain-1 mRNA expression remained unchanged, whereas atrogin-1 mRNA expression was increased by both wtSOD1 and mutSOD1 [54] . Thus mutSOD1 expression directly and specifically alters transcriptional regulation in muscle cells even in the absence of mutSOD1 aggregates. Translating these data from cells to animal models, with microarray analyses performed on mRNA derived from soleus and gastrocnemius muscles of tg ALS mice, the existence of alterations of several genes has been confirmed. The expression of a number of these genes was also changed in non-tg axotomized mice (acute denervated muscles) [55] . Thus the exact contribution of mutSOD1 toxicity on muscle cells is unclear compared with that arising from damaged motoneurons with denervated muscle. We thus further evaluated alterations in the expression of genes controlling muscle physiology and involved in muscle pathology, which we have tested previously in our muscle cell model of ALS [54] . Our analysis was designed to include muscle derived from tg ALS mice collected at disease onset and at various stages of disease progression. We found that wtSOD1 expression did not affect mRNA levels of MyoD and myogenin at all ages considered, whereas mutSOD1 expression induced a robust increase in MyoD and myogenin mRNA levels already at presymptomatic stages; this induction remained elevated at later symptomatic and end-stages [54] . Also atrogin-1 mRNA was found to be increased in muscle expressing mutSOD1 during disease progression, with very high levels at the symptomatic and end-stages. Interestingly, atrogin-1 mRNA increment was also found in muscle expressing wtSOD1, but only in the mice age-matched to end-stages of disease. Calpain-1 mRNA was unmodified under all conditions tested. TGFβ1 expression was similar in muscle of tg wtSOD1 and nontg mice at all ages tested, but highly up-regulated (up to 8-fold) in gastrocnemius muscles of mutSOD1 mice at all disease stages [54] . All of these data generally overlapped those obtained in the C2C12-based ALS model reported above, suggesting that these modifications may arise from direct mutSOD1 toxicity in muscle cells not mediated by the aggregation process. In fact, as reported above, mutSOD1 aggregation does not take place in muscle cells.
As a result of this and the elevated mutSOD1 clearance in muscle, we wanted to better investigate the role of degradative pathways in muscle of tg ALS mice. This was performed by analysing possible alterations in the expression of several genes involved in the cellular response to proteotoxicity; in particular, two autophagic markers, LC3 and p62, as well as the expression of chaperones and co-chaperones involved in protein quality control: Bag3, HSPB8 and Bag1. Our preliminary data indicate that LC3 expression was not significantly affected by mutSOD1. p62 was found to be increased (but only in female mice) at symptomatic stages, when compared with age-matched tg wtSOD1 and non-tg mice, or with pre-symptomatic mutSOD1 mice. HSPB8 and its interactor Bag3 were found to be significantly increased in mutSOD1 mice at symptomatic stages, and unaffected under all other conditions. Bag1 was not found to be modulated by mutSOD1 (V. Crippa, A. Boncoraglio, R. Galbiati, T. Aggarwal, P. Rusmini, E. Giorgetti, R. Cristofani, S. Carra, M. Pennuto and A. Poletti, unpublished work).
Conclusion
Taken together, these data strongly suggest that muscle cells are sensitive to toxicity of mutant misfolded proteins involved in ALS. However, muscle cells respond better and have a higher capability than motoneurons to handle these misfolded proteins. The increased chaperone response together with more efficient degradative pathways in muscle than in motoneurons allow for the prevention of misfolded protein intracellular aggregation. Therefore the toxicity exerted by mutant misfolded proteins in muscle cells is probably not related to the classical mechanism of intracellular aggregation, but another mechanism of toxicity may be involved.
